Free Trial
Evan David Seigerman

Evan David Seigerman Analyst Performance

BioPharma Analyst at BMO Capital Markets

Evan David Seigerman is a stock analyst at BMO Capital Markets, covering 8 publicly traded companies across a range of sectors. Over the past year, Evan David Seigerman has issued 10 stock ratings, including buy, hold, and sell recommendations. While full access to Evan David Seigerman's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan David Seigerman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 0 Years
Buy Recommendations
80.00% 8 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy80.0%8 ratings
Hold10.0%1 ratings
Sell10.0%1 ratings

Out of 10 total stock ratings issued by Evan David Seigerman at BMO Capital Markets, the majority (80.0%) have been Buy recommendations, followed by 10.0% Hold and 10.0% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
6 companies
NYSE
25.0% of companies on NYSE
2 companies

Evan David Seigerman, an analyst at BMO Capital Markets, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Evan David Seigerman of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
75.0%
LARGE CAP PHARMA
2 companies
25.0%

About Evan David Seigerman

Evan is a Managing Director and Senior Research Analyst at BMO Capital Markets covering Biotechnology (Large and SMid Cap) and US Major Pharmaceuticals. His responsibilities also include leading the therapeutics research effort at BMO, shaping strategy and growing impact of the broader franchise. Prior to joining BMO, Evan was a senior research analyst at Credit Suisse, also covering Biotechnology. He started his Wall Street Career at Deutsche Bank and later was on the #2 Institutional Investor ranked Biopharma team at Barclays. Before equity research, Evan was a strategy consultant for Major Pharma and Biotechnology clients. Recently, Evan was named a Rising Star of Equity Research by Business Insider and is consistently recognized by investors as a leading voice in the biotechnology space. He has been featured in countless media outlets, including CNBC, PBS News Hour, BNN Canada, The Wall Street Journal, Barron’s, The Economist, Kiplinger’s Personal Finance, The New York Times, and industry trade publications. Evan holds a BBA in Finance and Accounting and BA in Spanish, both from the University of Michigan.

Evan David Seigerman's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/23/2025Downgrade$2.81$2.00Underperform
Neurogene Inc. stock logo
NGNE
Neurogene
6/12/2025Reiterated Rating$21.56$26.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6/2/2025Lower Price Target$489.01$600.00Outperform
Merus N.V. stock logo
MRUS
Merus
5/23/2025Set Price Target$54.31$110.00Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
5/19/2025Boost Price Target$21.94$28.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
5/5/2025Lower Price Target$7.72$10.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/30/2025Lower Price Target$581.07$800.00Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4/17/2025Reiterated Rating$62.88$64.00Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
2/3/2025Boost Price Target$183.90$215.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
1/22/2025Boost Price Target$13.20$27.00Outperform